Related Experiment Video
Updated: Jun 23, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype-Matched Therapy: A
Kazusa Nofuji1, Tasuku Mariya1,2, Tomohiro Kubo3
1Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Sapporo, Japan, sapmed.ac.jp.
Obstetrics and Gynecology International
|June 22, 2026
Summary
Comprehensive cancer genomic profiling (CGP) in gynecologic cancers identified actionable alterations in 95.5% of cases. Early CGP testing and PIK3CA-focused trials may improve outcomes for these cancers.
Area of Science:
- Oncology
- Genomics
- Personalized Medicine
Background:
- Personalized medicine for gynecologic cancers is emerging but faces challenges.
- Comprehensive cancer genomic profiling (CGP) offers insights into targeted therapies.
Purpose of the Study:
- To evaluate the current status and clinical utility of CGP in gynecologic cancers at our institution.
- To identify challenges and opportunities for improving patient outcomes through CGP.
Main Methods:
- Prospective analysis of 44 gynecologic cancer cases undergoing CGP (FoundationOne CDx or Liquid CDx) from March 2020 to July 2022.
- Evaluation of CGP results, including actionable genomic alterations and potential for genotype-matched therapy (GMT).
- Survival analysis using Cox proportional hazards model to assess prognostic factors.
Main Results:
- Actionable genomic alterations were found in 95.5% of cases, with 36.4% eligible for genotype-matched therapy (GMT).
- GMT was administered in only 6.8% of eligible cases due to clinical factors or complications.
- PIK3CA mutations were associated with an adverse prognosis (HR: 2.73, p=0.023).
Conclusions:
- Earlier CGP testing can increase opportunities for genotype-matched therapy in gynecologic cancers.
- Proactive integration of PIK3CA-related clinical trials may enhance treatment strategies.
- Addressing implementation challenges is crucial for maximizing the benefit of CGP in gynecologic oncology.